Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Other financing activities (2018 - 2025)

Xtant Medical Holdings (XTNT) reported Other financing activities of $15000.0 for Q2 2025, down 91.62% year-over-year from $179000.0 in Q2 2024, and down 55.88% on a QoQ basis from $34000.0 in Q1 2025.

Xtant Medical Holdings (XTNT) has 6 years of Other financing activities data on file, last reported at $15000.0 in Q2 2025.

  • Quarterly Other financing activities fell 91.62% year-over-year to $15000.0 in Q2 2025, while the trailing twelve-month figure through Sep 2025 was $52000.0 (down 92.67% YoY) and the FY2024 annual result came in at $651000.0, up 172.38% from the prior year.
  • Other financing activities fell to $15000.0 in Q2 2025 per XTNT's latest filing, from $34000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $436000.0 in Q1 2024 and bottomed at $3000.0 in Q4 2024.
  • The 4-year median for Other financing activities is $40000.0 (2023), against an average of $100555.6.
  • The widest annual swing landed in 2024, when Other financing activities soared 990.0%; it then slumped 92.2% in 2025.
  • Tracing XTNT's Other financing activities over 4 years: stood at $104000.0 in 2021, then plunged by 41.35% to $61000.0 in 2023, then tumbled by 95.08% to $3000.0 in 2024, then soared by 400.0% to $15000.0 in 2025.
  • Per Business Quant, the three latest XTNT Other financing activities figures stand at $15000.0 (Q2 2025), $34000.0 (Q1 2025), and $3000.0 (Q4 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Xtant Medical Holdings 64.46 Mn 47.14 Mn 17.75 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 15,000.00
Jun 30, 2025 15,000.00
Mar 31, 2025 34,000.00
Mar 31, 2025 34,000.00
Dec 31, 2024 3,000.00
Dec 31, 2024 3,000.00
Sep 30, 2024 33,000.00
Sep 30, 2024 33,000.00
Jun 30, 2024 179,000.00
Jun 30, 2024 179,000.00
Mar 31, 2024 436,000.00
Mar 31, 2024 436,000.00
Jun 30, 2023 61,000.00
Jun 30, 2023 61,000.00
Mar 31, 2023 40,000.00
Mar 31, 2023 40,000.00
Sep 30, 2021 104,000.00
Sep 30, 2021 104,000.00
Sep 30, 2019 95,000.00
Sep 30, 2019 95,000.00
Jun 30, 2019 39,000.00
Jun 30, 2019 39,000.00
Mar 31, 2019 122,000.00
Mar 31, 2019 122,000.00
Dec 31, 2018 366,000.00
Dec 31, 2018 366,000.00
Sep 30, 2018 85,000.00
Sep 30, 2018 85,000.00
Jun 30, 2018 -1,000.00
Jun 30, 2018 -1,000.00
Mar 31, 2018 364,000.00
Mar 31, 2018 364,000.00